Hangzhou Tigermed Consulting Co., Ltd (HNGZY)
OTCMKTS
· Delayed Price · Currency is USD
4.000
0.00 (0.00%)
Jan 23, 2025, 7:00 PM EST
HNGZY Revenue
In the year 2024, Hangzhou Tigermed Consulting had annual revenue of 6.60B CNY, down -10.58%. Hangzhou Tigermed Consulting had revenue of 1.54B in the quarter ending December 31, 2024, a decrease of -11.42%.
Revenue
6.60B CNY
Revenue Growth
-10.58%
P/S Ratio
n/a
Revenue / Employee
680.66K CNY
Employees
9,701
Market Cap
5.88B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.60B | -780.92M | -10.58% |
Dec 31, 2023 | 7.38B | 298.57M | 4.21% |
Jan 1, 2023 | 7.09B | 1.87B | 35.91% |
Jan 1, 2022 | 5.21B | 2.02B | 63.32% |
Dec 31, 2020 | 3.19B | 388.97M | 13.88% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
Hangzhou Tigermed Consulting News
- 7 months ago - Hangzhou Tigermed Consulting reports Q2 results - Seeking Alpha